Collectively, these findings support previous reports that increased inflammation may follow or induce non-AIDS comorbidities, and further pinpoint PD-L1, VEGFA, LAP TGFβ-1, and TNFRSF9 as possible targets to decrease the risk for malignancies in well-treated PLHIV. This evidence concerns the gene TGFB1 and AIDS.